Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests
- Richard F A Logan1,
- Julietta Patnick2,
- Claire Nickerson2,
- Lynn Coleman2,
- Matt D Rutter3,
- Christian von Wagner4
- on behalf of the English Bowel Cancer Screening Evaluation Committee
- 1Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
- 2NHS Cancer Screening Programmes, Sheffield, UK
- 3Tees Bowel Cancer Screening Centre, University Hospital of North Tees, Stockton-on-Tees,UK
- 4Health Behaviour Research Centre, Department of Epidemiology and Public Health, UCL, London, UK
- Correspondence to Professor R F A Logan, Director of Eastern Hub of BCSP, Division of Epidemiology and Public Health, University of Nottingham Medical School, Nottingham NG7 2UH, UK;
Contributors RFAL conceived the study, analysed the data, and wrote the manuscript. JP conceived the study, and contributed to writing the manuscript. CN provided and contributed to analysing the data. LC contributed to writing the manuscript. MDR contributed to analysing the data and writing the manuscript. CvW contributed data and contributed to the analysis
- Received 19 July 2011
- Accepted 30 September 2011
- Published Online First 7 December 2011
Introduction The Bowel Cancer Screening Programme in England began operating in 2006 with the aim of full roll out across England by December 2009. Subjects aged 60–69 are being invited to complete three guaiac faecal occult blood tests (6 windows) every 2 years. The programme aims to reduce mortality from colorectal cancer by 16% in those invited for screening.
Methods All subjects eligible for screening in the National Health Service in England are included on one database, which is populated from National Health Service registration data covering about 98% of the population of England. This analysis is only of subjects invited to participate in the first (prevalent) round of screening.
Results By October 2008 almost 2.1 million had been invited to participate, with tests being returned by 49.6% of men and 54.4% of women invited. Uptake ranged between 55–60% across the four provincial hubs which administer the programme but was lower in the London hub (40%). Of the 1.08 million returning tests 2.5% of men and 1.5% of women had an abnormal test. 17 518 (10 608 M, 6910 F) underwent investigation, with 98% having a colonoscopy as their first investigation. Cancer (n=1772) and higher risk adenomas (n=6543) were found in 11.6% and 43% of men and 7.8% and 29% of women investigated, respectively. 71% of cancers were ‘early’ (10% polyp cancer, 32% Dukes A, 30% Dukes B) and 77% were left-sided (29% rectal, 45% sigmoid) with only 14% being right-sided compared with expected figures of 67% and 24% for left and right side from UK cancer registration.
Conclusion In this first round of screening in England uptake and fecal occult blood test positivity was in line with that from the pilot and the original European trials. Although there was the expected improvement in cancer stage at diagnosis, the proportion with left-sided cancers was higher than expected.
- colorectal cancer
- celiac disease
- gastrointestinal bleeding
- IBD clinical
- gastrointestinal cancer
- Helicobacter Pylori
- colonic adenomas
- colorectal cancer screening
- inflammatory bowel disease
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.